Wire · operational-macro
Fixing the controlled substance quota system: Why the law and the regulator must change
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The current DEA-controlled quota system for controlled substances in the US creates rigid supply limits causing chronic shortages of essential injectable opioids and ADHD stimulants despite federal resilience policies. The article proposes shifting quota administration from DEA to FDA to align production with patient needs and improve supply chain flexibility.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
You must reframe US controlled substance supply constraints as a regulatory bottleneck, not just a supply issue. This opens a legislative window to shift quota control to FDA, which directly improves market access and supply flexibility for pharmaceutical founders targeting ADHD stimulants and opioids.
◆ Coverage
1 source · 10 Sep 2026
◆ Related on Wire
◆ Topics